Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Rare Disease

Rare Disease

Strategic Consulting: The convergence revolution to innovate clinical trial process

May 10th, 2019 | Rare Disease

Strategic Consulting – SCIO Process -A New Way for Drug Development

April 30th, 2019 | Rare Disease

Strategic consulting reduces cost and risk of clinical trials

April 2nd, 2019 | Rare Disease

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Rare Disease

Welcome to BBCR’s New Website!

December 7th, 2018 | Rare Disease
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.
  • BBCR’s mission is to support domestic and international pharma, biotech, and device companies by nurturing their products’ strengths, while improving efficiency and safety. We specialize in strategy and provide early clinical research services to enable informed, timely decision-making for our clients.
  • BBCR brings deep expertise in early-stage development, including Phase 1 and Phase 2 process and strategy, spanning pre-clinical work through pre-IND. Our early drug development capabilities encompass clinical strategy and planning, including the creation of target product profiles and the design of clinical protocols.
  • BBCR partners with clients to identify, develop, and advance a product’s unique strengths from early concept through to market. Our consultancy is grounded in deep expertise across cell, biologic, and gene therapies, with a particular focus on rare disease.
  • BBCR’s team of experts help clients match treatments to rare genetic conditions and unsolved diseases, then work collaboratively with a product developer on the best plan to market. To learn more, visit bbcrconsulting.com.

RSS Nasdaq Globe Newswire

  • Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML April 24, 2026
  • LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer April 23, 2026
  • PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses April 23, 2026
  • Ocugen to Present at April 2026 Investor and Industry Conferences April 23, 2026
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2026 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs